Regimen Reference Order

BRST – trastuzumab emtansine (KADCYLA) Metastatic

ARIA: BRST – [trastuzumab emtansine (KADCYLA) MET]

Planned Course: **Every 3 weeks until disease progression or unacceptable toxicities**
Indication for Use: **Breast Cancer Metastatic or Locally Advanced, HER2 Positive**

CVAD: At Provider's Discretion

Proceed with treatment if:
ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L
- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – trastuzumab emtansine (KADCYLA) Metastatic

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycle 1 ONLY		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
trastuzumab emtansine (KADCYLA®)	3.6 mg/kg	IV in normal saline 250 mL over 90 minutes Use 0.2 or 0.22 micron filter ** Pharmacy Alert: This is a look-alike and sound-alike medication. Refer to Additional Information* **Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order*
Cycle 2 and Onwards		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
trastuzumab emtansine (KADCYLA®)	3.6 mg/kg	IV in normal saline 250 mL over 30 minutes Use 0.2 or 0.22 micron filter ** Pharmacy Alert: This is a look-alike and sound-alike medication. Refer to Additional Information* **Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order*

All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order**'

REQUIRED MONITORING

Cardiac Monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 4 cycles for the first 2 years then every 4 to 8 cycles thereafter

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Cycle 1

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 90 minutes after infusion (first dose). Full vital signs prior to discharge

Cycles 2 and 3

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after infusion. Full vital signs prior to discharge

Cycles 4 and Onwards

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- There is a risk of medication errors between trastuzumab emtansine (KADCYLA®), trastuzumab deruxtecan (ENHERTU®) and trastuzumab. In order to minimize the risk, check the regimen ordered, the vial labels, and the prescription label to ensure that the drug being prepared and administered is **trastuzumab emtansine (KADCYLA)**